Search: WFRF:(Gronbaek Kirsten) >
Molecular Monitorin...
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
-
- Kolstad, Arne (author)
- Oslo Univ Hosp, Radiumhospitalet, Dept Oncol, Oslo, Norway.,Oslo university hospital
-
- Pedersen, Lone Bredo (author)
- Copenhagen Univ Hosp, Rigshospitalet, Dept Hematol, Copenhagen, Denmark.,Copenhagen University Hospital
-
- Eskelund, Christian W. (author)
- Copenhagen Univ Hosp, Rigshospitalet, Dept Hematol, Copenhagen, Denmark.,Copenhagen University Hospital
-
show more...
-
- Husby, Simon (author)
- Copenhagen Univ Hosp, Rigshospitalet, Dept Hematol, Copenhagen, Denmark.,Copenhagen University Hospital
-
- Gronbaek, Kirsten (author)
- Copenhagen Univ Hosp, Rigshospitalet, Dept Hematol, Copenhagen, Denmark.
-
- Jerkeman, Mats (author)
- Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
-
- Laurell, Anna (author)
- Uppsala universitet,Experimentell och klinisk onkologi,Uppsala University Hospital
-
- Raty, Riikka (author)
- Univ Helsinki, Cent Hosp, Dept Hematol & Oncol, Helsinki, Finland.,Helsinki University Central Hospital
-
- Elonen, Erkki (author)
- Karolinska Institutet
-
- Andersen, Niels Smedegaard (author)
- Copenhagen Univ Hosp, Rigshospitalet, Dept Hematol, Copenhagen, Denmark.,Copenhagen University Hospital
-
- Brown, Peter deNully (author)
- Copenhagen Univ Hosp, Rigshospitalet, Dept Hematol, Copenhagen, Denmark.,Copenhagen University Hospital
-
- Kimby, Eva (author)
- Karolinska Institute
-
- Bentzen, Hans (author)
- Aarhus Univ Hosp, Dept Hematol, DK-8000 Aarhus, Denmark.,Aarhus University Hospital
-
- Sundström, Christer (author)
- Uppsala universitet,Klinisk och experimentell patologi,Department of Pathology, Uppsala University Hospital, Uppsala, Sweden.,Rose-Marie Amini
-
- Ehinger, Mats (author)
- Lund University,Lunds universitet,Uppsala universitet,Institutionen för immunologi, genetik och patologi,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
-
- Karjalainen-Lindsberg, Marja-Liisa (author)
- Skane Univ Hosp, Dept Pathol, Lund, Sweden.,Helsinki University Central Hospital
-
- Delabie, Jan (author)
- Helsinki Univ Cent Hosp, Dept Pathol, Helsinki, Finland.,Oslo university hospital
-
- Ralfkiaer, Elisabeth (author)
- Copenhagen Univ Hosp, Rigshospitalet, Dept Hematol, Copenhagen, Denmark.;Oslo Univ Hosp, Dept Pathol, Oslo, Norway.,Copenhagen University Hospital
-
- Fagerli, Unn-Merete (author)
- Copenhagen Univ Hosp, Rigshospitalet, Dept Pathol, Copenhagen, Denmark.,St. Olav’s University Hospital
-
- Nilsson-Ehle, Herman (author)
- St Olavs Univ Hosp, Dept Oncol, Trondheim, Norway.,Sahlgrenska University Hospital
-
- Lauritzsen, Grete Fossum (author)
- Oslo Univ Hosp, Radiumhospitalet, Dept Oncol, Oslo, Norway.,Oslo university hospital
-
- Kuittinen, Outi (author)
- Sahlgrens Univ Hosp, Dept Hematol, Gothenburg, Sweden. Oulu Univ Hosp, Dept Oncol, Oulu, Finland.,Oulu University Hospital
-
- Niemann, Carsten (author)
- Copenhagen Univ Hosp, Rigshospitalet, Dept Hematol, Copenhagen, Denmark.,Copenhagen University Hospital
-
- Geisler, Christian Hartman (author)
- Copenhagen Univ Hosp, Rigshospitalet, Dept Hematol, Copenhagen, Denmark.,Copenhagen University Hospital
-
- Grønbæk, Kirsten (author)
- Copenhagen University Hospital
-
show less...
-
Oslo Univ Hosp, Radiumhospitalet, Dept Oncol, Oslo, Norway Oslo university hospital (creator_code:org_t)
- ELSEVIER SCIENCE INC, 2017
- 2017
- English.
-
In: Biology of blood and marrow transplantation. - : ELSEVIER SCIENCE INC. - 1083-8791 .- 1523-6536. ; 23:3, s. 428-435
- Related links:
-
http://www.bbmt.org/...
-
show more...
-
http://dx.doi.org/10...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow of patients with mantle cell lymphoma (MCL) to predict clinical relapse and guide preemptive treatment with rituximab. Among the patients enrolled in 2 prospective trials by the Nordic Lymphoma Group, 183 who had completed autologous stem cell transplantation (ASCT) and in whom an MRD marker had been obtained were included in our analysis. Fresh samples of bone marrow were analyzed for MRD by a combined standard nested and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain gene (IgH) and clonal IgH rear-rangements. Significantly shorter progression-free survival (PFS) and overall survival (OS) was demonstrated for patients who were MRD positive pre-ASCT (54 patients) or in the first analysis post-ASCT (23 patients). The median PFS was only 20 months in those who were MRD-positive in the first sample post-ASCT, compared with 142 months in the MRD-negative group (P <.0001). OS was 75% at 10 years and median not reached in the MRD-negative group, compared with only 35 months in the MRD-positive group (P <.0001). Of the 86 patients (47%) who remained in continuous molecular remission, 73% were still in clinical remission after 10 years. For all patients, the median time from ASCT to first molecular relapse was 55 months, with a continuous occurrence of late molecular relapses. Fifty-eight patients who experienced MRD relapse received rituximab as preemptive treatment on 1 or more occasions, and in this group, the median time from first molecular relapse to clinical relapse was 55 months. In most cases, rituximab converted patients to MRD negativity (87%), but many patients became MRD-positive again later during follow-up (69%). By multivariate analysis, high-risk Mantle Cell Lymphoma International Prognostic Index score and positive MRD status pre-ASCT predicted early molecular relapse. In conclusion, preemptive rituximab treatment converts patients to MRD negativity and likely postpones clinical relapse. Molecular monitoring offers an opportunity to select some patients for therapeutic intervention and to avoid unnecessary treatment in others. MRD-positive patients in the first analysis post-ASCT have a dismal prognosis and thus are in need of novel strategies.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Klinisk laboratoriemedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Clinical Laboratory Medicine (hsv//eng)
Keyword
- Mantle cell lymphoma
- Autologous stem cell
- transplantation
- Minimal residual disease
- Preemptive rituximab
- Patologi
- Pathology
- Autologous stem cell transplantation
- Mantle cell lymphoma
- Minimal residual disease
- Preemptive rituximab
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Kolstad, Arne
-
Pedersen, Lone B ...
-
Eskelund, Christ ...
-
Husby, Simon
-
Gronbaek, Kirste ...
-
Jerkeman, Mats
-
show more...
-
Laurell, Anna
-
Raty, Riikka
-
Elonen, Erkki
-
Andersen, Niels ...
-
Brown, Peter deN ...
-
Kimby, Eva
-
Bentzen, Hans
-
Sundström, Chris ...
-
Ehinger, Mats
-
Karjalainen-Lind ...
-
Delabie, Jan
-
Ralfkiaer, Elisa ...
-
Fagerli, Unn-Mer ...
-
Nilsson-Ehle, He ...
-
Lauritzsen, Gret ...
-
Kuittinen, Outi
-
Niemann, Carsten
-
Geisler, Christi ...
-
Grønbæk, Kirsten
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Clinical Laborat ...
- Articles in the publication
-
Biology of blood ...
- By the university
-
Uppsala University
-
Lund University
-
Karolinska Institutet